Media Overview

Boehringer Ingeheim’s Hub for providing you with the latest Press Releases and further Press Material for Download.

Press Releases

[First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline](/content/hk/en/about-us/who-we-are/first-half-2022-boehringer-ingelheim-continues-growth-pace-and-strengthens-research-pipeline "First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline"/index.html)

August 03, 2022

First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

[Read more](/content/hk/en/about-us/who-we-are/first-half-2022-boehringer-ingelheim-continues-growth-pace-and-strengthens-research-pipeline "Read more about "First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline""/index.html)

[CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction](/content/hk/en/human-health/heart-diseases/heart-failure/jiyuzaishexuefenshubaoliudechengrenxinlishuaijiehuanzhezhongqiansuoweiyoudehuoyichmpfabulekuodajardi "基于在射血分数保留的成人心力衰竭患者中前所未有的获益，CHMP发布了扩大Jardiance（恩格列净）适应症的积极意见"/index.html)

June 28, 2022

CHMP issues positive opinion to expand Jardiance (empagliflozin) indication based on unprecedented benefit in adult heart failure patients with preserved ejection fraction

Read more

[Stop of treatment in COVID-19 study](/content/hk/en/stop-treatment-covid-19-study "Stop of treatment in COVID-19 study"/index.html)

June 23, 2022

Stop of treatment in COVID-19 study

[Read more](/content/hk/en/stop-treatment-covid-19-study "Read more about "Stop of treatment in COVID-19 study""/index.html)

Current Events

Please check back later!

There are no upcoming events in the near future.

Past Events

Please check back later!

There are no upcoming events in the near future.

References